About Us

For more than a decade, Glycominds has been a forerunner in Inflammatory Bowel Disease (IBD) biomarkers research, bringing exciting and innovative products to market, including IBDX—a diagnostic and disease-progression biomarker system for IBD and Crohn’s Disease (CD). Developed in Glycominds laboratories studying thousands of patient samples in collaboration with global key opinion leaders, the proprietary IBDX technology platform takes the standard of glycan-based-marker systems to a new level.